Loading clinical trials...
Loading clinical trials...
A 24-week Open-label, Multicenter, Follow-up and Extension Study to CACZ885H2251, to Assess Safety, Tolerability and Efficacy of Canakinumab (ACZ885) in Patients With Gout Who Were Given Canakinumab at the Time of Gout Flare
Conditions
Interventions
Canakinumab
Locations
45
United States
Novartis Investigative site
Seattle, Washington, United States
Novartis Investigative site
Capital Federal Buenos Aires, Argentina
Novartis Investigative site
Jette, Belgium
Novartis Investigative site
Barranquilla, Colombia
Novartis Investigative site
Bogotá, Colombia
Novartis Investigative site
Bucaramanga, Colombia
Start Date
June 5, 2009
Primary Completion Date
August 4, 2010
Completion Date
August 4, 2010
Last Updated
July 2, 2021
NCT07453004
NCT07116746
NCT06451848
NCT05332795
NCT06273813
NCT04734093
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions